Free shipping on all orders over $ 500

c-Myc c-Myc

Cat.No.  Name Information
M2353 10074-G5 10074-G5 is a c-Myc/Max interaction inhibitor, which binds to a different specific binding site (region) of C-Myc than 10054-F4.
M2352 10058-F4 10058-F4 is a c-Myc inhibitor that specificallly inhibits the c-Myc-Max interaction and prevents transactivation of c-Myc target gene expression.
M13541 Mycro 3 Mycro 3 is a potent and selective inhibitor of Myc-associated factor X (MAX) dimerization. Mycro 3 also inhibit DNA binding of c-Myc. Mycro 3 could be used for the research of pancreatic cancer.
M13539 APTO-253 APTO-253 (LOR-253) is a small molecule that inhibits c-Myc expression, stabilizes G-quadruplex DNA, and induces cell cycle arrest and apoptosis in acute myeloid leukemia cells.
M11420 MYCi975 MYCi975 (Nuc-0200975) is an orally active MYC inhibitor that disrupts MYC/MAX interactions, promotes MYC T58 phosphorylation and MYC degradation, and impairs myC-driven gene expression. MYCi975 (NUC-0200975) has strong anti-tumor effect and good tolerance, increasing tumor immune cell infiltration and enhancing tumor sensitivity against PD1 immune studies.
M9309 ML327 ML327 is a blocker of MYC, which mediated transcriptional de-repression of E-cadherin and inhibition of epithelial-to-mesenchymal transition.
M45231 Omomyc Omomyc is a cell-penetrating peptide derived from the bHLH structural domain of Myc. When expressed in cells, Omomyc inhibits C-Myc-mediated transcription and suppresses cell proliferation.Omomyc competes with C-Myc for binding to Max, resulting in the formation of the Omomyc/Max complex, which competes with the endogenous c-Myc/Max heterodimer and ultimately inhibits transcriptional activation resulting in Myc target genes involved in proliferation and metabolism.
M41339 MDEG-541 MDEG-541 is a potent MYC-MAX degrader.
M41338 c-Myc inhibitor 11 c-Myc inhibitor 11 is a c-MYC inhibitor (pEC50: 6.4).
M41337 c-Myc inhibitor 12 c-Myc inhibitor 12 is an inhibitor of c-Myc with a pEC50 of 6.4.
M41336 m-Se3 m-Se3 is a potent and selective c-MYC transcription inhibitor that can inhibit tumor growth and has anti-cancer activity.
M41335 c-Myc inhibitor 10 c-Myc inhibitor 10, a c-Myc inhibitor, exhibits increased cellular potency, consistent with an increase in permeability with methylation of the morpholine nitrogen.
M41334 MYC-RIBOTAC MYC-RIBOTAC is a ribonuclease-targeting chimera (RIBOTAC) to MYC internal ribosome entry site (IRES).
M30814 NY2267  NY2267 is a disruptor of Myc-Max interaction, with an IC50 of 36.5 μM. NY2267 inhibits Myc- and Jun-induced transcriptional activation.
M30474 MYCMI-6 MYCMI-6 (NSC354961) is a potent and selective endogenous MYC:MAX protein interactions inhibitor. MYCMI-6 blocks MYC-driven transcription and binds selectively to the MYC bHLHZip domain with a Kd of 1.6 μM. MYCMI-6 inhibits tumor cell growth in a MYC-dependent manner (IC50<0.5 μM). MYCMI-6 is not cytotoxic to normal human cells. MYCMI-6 induces apoptosis.
M30320 KJ Pyr 9  KJ Pyr 9 is an inhibitor of MYC with a Kd of 6.5 nM in in vitro assay.
M29830 c-Myc inhibitor 9  c-Myc inhibitor 9 (compound 332) is a c-Myc inhibitor with an logEC50 of ≥6. c-Myc inhibitor 9 inhibits tumor growth in nude mouse models. c-Myc inhibitor 9 can be used for cancer research.
M29711 CMLD010509 CMLD010509 (SDS-1-021) is a highly specific inhibitor of the oncogenic translation program supporting multiple myeloma (MM)-including key oncoproteins such as MYC, MDM2, CCND1, MAF, and MCL-1. CMLD010509 (SDS-1-021) shows an IC50 below 10 nM for most MM cell lines and induces apoptosis. CMLD010509 (SDS-1-021) is a potent and selective translation inhibitor through an eIF4E phosphorylation-independent mechanism.
M29215 WBC100 WBC100 (14-D-Valine-TPL) is a potent, selective, and orally active c‐Myc molecule glue degrader. WBC100 is a c‐Myc degrader and targets ubiquitin E3 ligase CHIP mediated 26S proteasome pathway. WBC100 is used for c‐Myc overexpressing tumors research.
M20729 MYCi361 MYCi361 is a MYC inhibitor that engages MYC inside cells, disrupts MYC/MAX dimers, and impairs MYC-driven gene expression. MYCi361 binds to MYC with Kd of 3.2 μM. MYCi361 suppresses in vivo tumor growth, increases tumor immune cell infiltration, upregulates PD-L1 on tumors, and sensitizes tumors to anti-PD1 immunotherapy.




Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.